The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis

Abstract

Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies until August 10, 2021. The data on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were pooled. Furthermore, grade ≥ 3 adverse events (AEs) were investigated. Results A total of 13 studies with 3953 patients were included. Compared with control group, angiogenesis inhibitors resulted in significant improvement in PFS (hazard ratio (HR) = 0.61, 95%CI, 0.54–0.69), OS (HR = 0.88, 95%CI, 0.81–0.95), and ORR (odds ratio (OR) = 2.15, 95% CI, 1.74–2.65). However, angiogenesis inhibitors were associated with a higher risk of grade ≥ 3 AEs (relative risk (RR), 1.20, 95% CI, 1.04–1.38). Conclusion Angiogenesis inhibitors can improve ORR, PFS, and OS in patients with recurrent OC, but they can increase the incidence of AEs ≥ 3.

Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis

“…The Hall et al, 2020 [ 103 ] study was not included due to the fact that cyclophosphamide was used as a treatment line rather than carboplatin/paclitaxel—the superiority of combination carboplatin–paclitaxel over the cisplatin–cyclophosphamide combination was demonstrated by a previous trial [ 22 ], and the usage of cyclophosphamide may falsely alter the PFS results in favor of anti-angiogenetic drugs. The most recent meta-analysis on the subject of inhibitors of angiogenesis in ovarian-tumor patients we came across is the one performed by Zhang et al [ 104 ], referring only to recurrent ovarian tumors and containing 13 RTCs, which were all included in our study. The results of the Zhang et al meta-analysis had similar results to ours, indicating both an OS and a PFS benefit of anti-angiogenetic drugs in recurrent neoplasm.…”

Natural products exert anti-tumor effects by regulating exosomal ncRNA

“…Research has demonstrated that inhibition of angiogenesis can inhibit tumor growth and metastasis ( 73 ). Thus angiogenesis has emerged as a target for cancer therapy ( 74 ).…”

Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials

“…Nevertheless, debates persist regarding the OS advantage and the safety profile of these combined treatments ( Chekerov et al, 2018 ; Ray-Coquard et al, 2020 ; Pignata et al, 2021 ). Prior meta-analyses have explored the efficacy and toxicity of anti-angiogenic drugs in different subtypes of OC ( Yi et al, 2017 ; Helali et al, 2022 ; Zhang et al, 2022 ). However, there is a lack of a comprehensive meta-analysis to evaluate the effects of monotherapy or combination therapy with anti-angiogenic drugs on OC.…”